How Medicare contributed to GSK's top line (Hint: Advair)

Medicare spent $2.26 billion on GlaxoSmithKline's (NYSE: GSK) asthma drug, Advair Diskus, in 2013, making it the second-costliest drug for the government payer in 2013. More than 1.5 million beneficiaries filed 6.6 million claims for the inhalable dry powder that comes in the plastic purple dispensing device. Large portions of the drug and the device are produced in Zebulon. For the first time, Medicare publicly released detailed information on the prescription drugs that health providers prescribed…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news